Drugs / Tolilizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07667751 | Jun 2026 → Dec 2027 expected | ovarian cancer | Bai-Rong Xia | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tolilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07667751 ↗ |